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Gabriella Simbula,1 Ignazio Zedda,1 and Amedeo
Columbano
Liver cell proliferation has often been implicated to play a major role during different steps
of the carcinogenic process. Most of the experimental studies indicating a close association
between cell proliferation and liver cancer development have made use ofa compensatory type
ofproliferative stimulus. However, liver growth may also be caused by direct hyperplasia after
administration of primary mitogens. Our recent studies examined the possible differences
between these two types of cell proliferation. Our studies indicate that a) increased expression
of proto-oncogenes such as c-fos, c-jun, and c-myc is not necessary for entry into the cell cycle
during mitogen-induced liver growth; b) mitogen-induced liver growth does not support initia-
tion of chemical hepatocarcinogenesis; c) repeated proliferative stimuli induced by primary
mitogens do not stimulate the growth of initiated cells to a focal and/or nodular stage; and
d) mitogen-induced liver growth, unlike compensatory regeneration, is followed by a particular
mode of cell death, namely, apoptosis. This type of cell death may be responsible for the elimi-
nation ofcarcinogen-initiated cells.
Introduction
Cell proliferation appears to be intimately involved
in several phases ofthe carcinogenic process. Although
the detailed mechanism by which cell proliferation par-
ticipates in initiation, promotion, and progression phas-
es is far from understood, several epidemiological as
well as experimental studies have recently led many
investigators to hypothesize that any condition charac-
terized by enhanced cell division results in an accumu-
lation of genetic errors that may ultimately lead to
neoplasia (1-3). Interestingly, most of the information
about the role of cell proliferation in experimental car-
cinogenesis, especially data indicating a positive corre-
lation between cell proliferation and the initiation step
of liver chemical carcinogenesis, comes from experi-
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mental protocols wherein a compensatory type of pro-
liferative stimulus was used. In this article we summa-
rize our recent research presenting evidence that
there are at least two different types of proliferative
stimuli and that these two different stimuli may exert
different effects on initiation and promotion of hepato-
chemical carcinogenesis.
Compensatory Regeneration
Cell proliferation can be induced in the liver after
surgical removal ofcells [partial hepatectomy; PH (4)].
This regenerative growth seems to be under control of
a growth regulatory mechanism, and it stops once the
organ has reached its original mass. A similar regener-
ative growth can be observed in the liver after treat-
ment with several chemicals, including many carcino-
gens, that induce cell necrosis. This type of cell
proliferation, called compensatory regeneration, is pos-
itively correlated with the initiation phase of chemical
hepatocarcinogenesis (5-8). In recent years, this type
ofproliferative stimulus, especially after PH, has been
extensively characterized in terms ofexpression ofcel-
lular proto-oncogenes production of growth factors
such as HGF (hepatocyte growth factor) and trans-LEDDA-COLUMBANO ETAL.
forming growth factor TGFa, as well as of mito-
inhibitory signals such as TGF3 [for reviews see
Fausto and Mead (9) and Michalopoulos (10)].
Mitogen-Induced Liver Growth
Compensatory regeneration is not the only mode of
cell proliferation. Certain chemicals may induce
growth in organs such as the liver and kidney without
causing prior cell loss. These agents, called primary
mitogens, induce cell proliferation as the primary
event, thus increasing the mass ofthe organ due to an
increase in DNA content. After cessation of the mito-
genic stimulus, there is a rapid regression of the
hyperplasia until the organ reaches its original mass.
The regression of the original hyperplasia appears to
be due to a particular mode ofcell death, namely apop-
tosis (11). The fact that apoptotic bodies do not occur
until liver or renal cells have completed their replica-
tive cycle and the fact that apoptotic bodies are not
detected once the organs have regressed to their origi-
nal mass (12-14) support the hypothesis that apoptosis
is involved in the regulation oforgan size by playing a
complementary but opposite role to mitosis. Apoptosis
under these conditions may be referred to as "compen-
satory cell death," in the same way we define "compen-
satory regeneration" as the mitotic response ofa tissue
after cell removal.
It is also important to stress that mitogen-induced
liver growth occurs without any previous cell loss,
which seems to suggest that mitogens can interfere
with the regulatory mechanisms normally operating in
the target organ. The interference is only transient. In
fact, refractoriness of liver cells to proliferation is
observed after a few days, even in the presence ofthe
mitogenic stimulus. Based on the differences exhibited
by these two types of proliferative stimulus, we
designed experiments to study their effects in differ-
ent steps ofliver carcinogenesis.
Initiation of Liver Carcinogenesis
As already mentioned, several studies have shown
that proliferative stimuli of the compensatory type
applied before or immediately after administration ofa
non-necrogenic dose of carcinogens support the initia-
tion of chemical hepatocarcinogenesis (5-8). To study
whether different proliferative stimuli could exert a
different effect on the initiation phase, experimental
protocols were adopted wherein the same non-necro-
genic dose of the carcinogen N-methyl-N-nitrosourea
(MNU) was administered during compensatory regen-
eration induced by PH orCCl4 and duringlivergrowth
induced by the primary mitogen lead nitrate (LN). The
results obtained indicate that, unlike compensatory
regeneration, mitogen-induced liver growth did not
support initiation (15,16). Similar results were obtained
when other mitogens, such ethylene dibromide (EDB),
nafenopine (BAF), and cyproterone acetate (CPA), or
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FIGURE 1. Effect ofproliferative stimuli of different types on initia-
tion of chemical carcinogenesis. Male Wistar rats (200 g) were
given N-methyl-N-nitrosourea (60 mg/kg) during S phase after
induction of compensatory regeneration by partial hepatectomy
and CC14 (2 mL/kg) or mitogen-induced liver growth by lead
nitrate (100 gmole/kg), ethylene dibromide (100 mg/kg), cypro-
terone acetate (60 mg/kg), and nafenopin (200 mg/kg). The initiat-
ed hepatocytes were assayed as GST-P+ (placental glutathione-S-
transferase) foci after promotion with the resistant hepatocyte
model.
other carcinogens, such as benzo(a)pyrene (BaP) and
diethylnitrosamine (DEN), were used (Fig. 1). Similar
findings were obtained whether the initiated hepato-
cytes were monitored as enzyme-altered foci using the
resistant hepatocyte model [RH (17)] or using the phe-
nobarbital (PB) (18,19) or the orotic acid (OA) model
(20). Thus, it appears that only compensatory liver cell
proliferation, but not direct hyperplasia, supports car-
cinogen-induced initiation.
Development of Foci and Nodules
Cell proliferation is involved not only in the initiation
step of chemical carcinogenesis but also in the promo-
tion phase. A number ofexperimental findings suggest
that proliferative stimuli such as those exerted by PH
or necrogenic doses ofCCl4 promote the appearance of
nodules and hepatocellular carcinomas after initiation
with different carcinogens (21-23). In contrast, con-
flicting information comes from studies where mito-
gens were used as promoting agents in long-term regi-
mens. Although long-term feeding with mitogenic
compounds exerts a promoting effect on the growth of
preneoplastic and neoplastic lesions (24-27), it has
been reported that compounds with mitogenic activity
paradoxically accelerate the regression of enzyme-
altered foci (28-30). A precise assessment ofthe role of
cell proliferation during promotion ofliver carcinogen-
esis is further complicated by the fact that, with few
exceptions (24), the mitogenic compounds elicit a very
transient proliferative response of the liver (usually
the proliferative response is almost completely abol-
ished in a matter of days). Thus, under these condi-
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tions it is difficult to conceive of an association
between the promoting ability ofthese chemicals (pro-
motion requires a long time) and their capacity to
induce cell proliferation in the target organ, which is
limited to a few days. A specific effect of these com-
pounds on initiated cells rather than a generalized pro-
liferative stimulation in the target organ may better
justify the promoting ability ofthese chemicals.
To learn more about the relation between cell prolif-
eration and promotion, an experimental protocol was
adopted wherein rat liver was initiated with DEN and
then stimulated to proliferate by repeated administra-
tion of the necrogenic compound CC14 (compensatory
regeneration) or by repeated treatment with LN
(mitogen-induced liver growth). Under these experi-
mental conditions, it is possible to determine whether
a mitotic response of liver cells occurs any time the
proliferative stimulus is applied and to associate the
proliferative capacity ofthe two different proliferative
stimuli with their ability to promote the growth of car-
cinogen-initiated cells. The results obtained indicate
that y-glutamyltranspeptidase-(GGT)-positive foci
and/or nodules were observed only when cell prolifera-
tion was induced by CC14 (compensatory regeneration)
but not when the proliferative stimulus was represent-
ed by a primary mitogen (Fig. 2); this finding indicates
that liver growth induced by the mitogen LN, unlike
compensatory regeneration, does not possess any pro-
moting ability. Interestingly, the extent of cell prolif-
eration observed after the last proliferative stimulus
was essentially similar in both the experimental
groups, indicating that DNA synthesis per se is not a
sufficient condition for the growth of preneoplastic
lesions (31).
Development of Enzyme-Altered
Foci during Promotion
It is possible that in lead-nitrate-induced hyperplasia
there is no difference between initiated and normal
cells (lack of "differential"). To answer this question,
we designed an experimental protocol wherein the
"differential" was generated by the exposure ofinitiat-
ed liver cells to several promoting regimens. It is
known that in several models ofrat liver tumor promo-
tion, compensatory regeneration is either a necessary
component (resistant hepatocyte model) or it potenti-
ates the promoting ability ofpromoting agents such as
OA and PB (20,32,33). Therefore, we investigated
whether induction of mitogen-induced liver growth in
the presence of a promoting environment could now
enhance the growth ofinitiated cells to a focal or nodu-
lar stage. The results, which are shown in Table 1, indi-
cate that mitogenic stimulation induced by LN in rats
previously initiated with DEN to promoting regimens
such as OA or PB, unlike that exerted by PH, is unable
to potentiate the promoting ability of these agents.
Analysis of DNA synthesis in the various conditions
did not show any significant difference, again suggest-
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FIGURE 2. Incidence ofy-glutamyltranspeptidase-positive foci versus
hepatic cell proliferation after compensatory regeneration or
direct hyperplasia. Rats were treated with an initiating dose of
diethylnitrosamine (100 mg/kg). After 15 days, cell proliferation
was induced for 8 times, once every 20 days, by a compensatory
type ofproliferative stimulus (CCI4) or by direct hyperplasia (lead
nitrate). Incorporation oftritiated thymidine was measured at the
time ofsacrifice after the last injection ofCCI4 or lead nitrate.
ing a dramatic difference between these two types of
proliferative stimuli despite the fact that they both
stimulate a similar degree ofliver cell proliferation.
Conclusions
The following hypotheses may be considered to
explain the different effect ofthe two types ofliver cell
proliferative stimuli on initiation and promotion of
chemical hepatocarcinogenesis: a) mitogen-induced
hyperplasia is not conducive for the growth ofinitiated
cells; b) mitogen-induced hyperplasia stimulates the
growth of initiated cells, but initiated cells are elimi-
Table 1. Effect ofdifferent proliferative stimuli given dur-
ing promotion with OA on (3H)thymidine incorporation
into hepatic DNA and on the incidence ofGGT+ foci.a
[ H]Thymidine
Proliferative incorporation GGT+
Treatment stimulus (cpm/4gDNA) foci/cm2
DEN+ OA None 18 + 3 0.7 ± 0.2
DEN+ OA PH 90 ± 30 12.0 ± 1.0
DEN+OA LN 102 ± 7 1.2 ± 0.3
DEN+ BD PH ND 1.3 ± 0.6
DEN+ BD LN ND 0.7 ± 0.2
Abbreviations: ND, not determined; OA, orotic acid; GGT, y-glu-
tamyltranspeptidase; DEN, diethylnitrosamine; BD, basal diet; PH,
partial hepatectomy; LN, lead nitrate.
aDEN was given at a dose of 100 mg/kg IP. Two weeks after DEN
administration, rats were fed a diet containing 1% OA or BD. Liver
cell proliferation was induced 2 weeks later by PH or LN (100 micro-
mole/kg). For determination of thymidine incorporation, osmotic
minipumps containing [3 H]thymidine releasing a constant flow rate
of 1 iCi/hr were implanted IP, and the rats were killed 3 days after-
wards. For determination of the enzyme-altered foci, rats were sac-
rificed 2 weeks after application of the proliferative stimuli and the
foci were monitored as GGT+.
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nated by apoptosis during the regression phase. The
former hypothesis argues that the signal transduction
pathways for these two types ofgrowth stimuli are dif-
ferent. It is possible that although the normal hepato-
cytes may respond to both the proliferative stimuli,
initiated hepatocytes can respond to growth signals
induced by compensatory cell proliferation but not to
those induced by mitogen-induced direct hyperplasia.
In this respect, it is of interest that the signal trans-
duction pathways induced by these different growth
stimuli appear to be different. In fact, while a transient
and sequential expression of c-fos, c-jun, and c-myc is
induced in rat liver after CC14 and PH, hyperplasia
induced by the mitogen CPA is not accompanied by
any increase in the expression ofthese proto-oncogenes
(34). Preliminary studies indicate that a similar pattern
can be observed during hepatic cell growth induced by
NAF. Furthermore, no significant increase in the
expression of c-fos was observed during hyperplasia
induced by two other mitogens, LN and EDB. The dif-
ferences observed between the various proliferative
stimuli seem to concern immediate early genes. In fact,
an increased expression of genes associated with S
phase such as H-ras, K-ras, and thymidilate synthase
(TS) was observed in all proliferative conditions (Table
2). Whether these differences are a reflection of dif-
ferent pathways ofsignal transduction has to be inves-
tigated.
It is conceivable that primary mitogens use different
mechanisms leading to the entry into the cell cycle.
For example, the mitogens CPA (a synthetic steroid)
and NAF (a hypolipidemic drug) could exert their
effect by binding to a superfamily of intracellular
steroid hormone receptors (35). In this way these
chemicals could directly modulate specific gene tran-
scription. In contrast, another type ofcell growth stim-
ulus related to membrane receptors exerts this func-
tion through different transcription-activating factors
[AP1 family (36)]. Recent studies suggesting that
steroid receptors and AP1 factors are the primary reg-
ulators in two separate signal transduction pathways
(37) may possibly explain why CPA-induced hyperpla-
sia is not accompanied by an increased expression of
Table 2. Schematic representation ofthe pattern of
expression ofsome cell-cycle-related genes during cell
proliferation induced by different proliferative stimuli.
Compensatory regeneration Hyperplasia
Gene PH CC14 LN EDB CPA
c-fos T T
c-jun T T T T
c-myc T 1 T T
c-Ha-ras T T T T t
TS T T T T 1
Abbreviations: PH, partial hepatectomy, LN, lead nitrate; EDB,
ethylene dibromide; CPA, cyproterone acetate; TS, thymidilate syn-
thase.
c-fos, c-jun, and c-myc mRNA, while an increased
expression of these proto-oncogenes is present during
cell proliferation induced by stimuli of a different
nature.
Another possibility is that mitogens induce growth
factors that are different from those induced during
compensatory regeneration. It will be of interest to
determine whether mitogen-induced liver growth is
associated with an increase in growth factors such as
HGF or TGFa, as observed during CC14, galac-
tosamine, or PH-induced compensatory regeneration
(38,39). It will also be ofinterest to determine whether
a difference exists in terms of modulation of positive
and negative growth-regulating factors between the
two types ofproliferative stimuli.
As mentioned above, another possible explanation
for the absence of enzyme-altered hepatic lesions in
mitogen-treated rat liver is that initiated cells divide
after the mitogenic stimulus, but they are eliminated
by apoptosis during the regression ofthe initial hyper-
plasia (16). The possibility that this type of cell death
might be responsible for the lack of foci formation
implies that initiated cells are susceptible to apoptosis
as much or even more than normal hepatocytes. This
possibility is supported by studies based on mathemat-
ical models that indicated an extensive loss ofinitiated
cells shortly after their formation (40). In this respect,
it is also interesting to note that preneoplastic liver
cells induced by three different promoting procedures,
the RH model, the CD model, and the OA model, show
a high apoptotic index at the early stage ofthe process
(41). In this study as well as in other reports, the inci-
dence ofapoptotic bodies was found to be much higher
in preneoplastic hepatocytes than in surrounding nor-
mal cells (12,41,42), suggesting that carcinogen-initiat-
ed liver cells (that are quite resistant to necrosis) are
somehow more sensitive than normal cells to apopto-
sis. The possibility that carcinogen-altered cells may
be preferentially eliminated by apoptosis is very
intriguing. In fact, it may be hypothesized that induc-
tion ofapoptosis at a time when initiated cells have not
yet undergone the changes responsible for their neo-
plastic development may selectively kill these cells
without severe loss ofnormal hepatocytes (43).
On the other hand, carcinogen-altered hepatocytes
are generally believed to be more resistant than nor-
mal cells to another type of cell death, necrosis. It is
known that administration of compounds such as CCl4
and dimethylnitrosamine at doses that induce severe
necrosis in normal liver do not elicit necrosis ofhepato-
cytes ofpreneoplastic lesions (44). The possibility that
initiated hepatocytes may be resistant to one type of
cell death (necrosis) but not to the other (apoptosis)
deserves consideration. Although at present we do not
understand the exact significance of apoptosis in the
carcinogenic process, an in-depth study of the mecha-
nisms underlying the differences between this type of
cell death and cell necrosis may help to clarify the
mechanism(s) responsible for the inability of mitogen-
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induced cell proliferation to support the growth ofcar-
cinogen-initiated cells.
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